Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Hippocampal subfield volumetry for predicting cognitive impairment in Parkinson’s disease
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
158

To assess the prognostic value of hippocampal subfield volumes in predicting future cognitive status in terms of Level I Mild Cognitive Impairment (MCI) criteria.

Hippocampal atrophy has been associated with cognitive impairment in Parkinson’s disease (PD) patients. As a structure, the hippocampus has several subdivisions, as defined by histology and cytoarchitecture. However, the associations between cognitive status and individual hippocampal subfield volumes have not been widely characterized. 

148 PD patients from the Parkinson’s Progression Markers Initiative (PPMI) were selected and their baseline 3D T1-weighted image was processed with FreeSurfer and the hippocampus subfields module. Individual subfield and total hippocampal volumes were extracted. ANCOVA models, correcting for age, sex, and total intracranial volume, were used to compare hippocampal volumetry between PD patients with and without Level I MCI at baseline as well as after 3 and 4 years of follow-up.

At baseline, PD MCI had lower total hippocampal volume (p=0.008) and lower volumes for the hippocampal subfields including the tail (p=0.014), subiculum (p=0.047), cornu ammonis (CA) 1 (p=0.030), presubiculum (p=0.011), molecular layer HP (0.016), molecular and granule cell layers of the dentate gyrus (0.044) and CA4 (p=0.039) compared to PD with normal cognition. Lower baseline CA1 volume was also associated with MCI status at year 4 (p=0.035). When excluding the 22 patients with MCI at baseline, lower baseline total hippocampal volume and tail volume were associated with conversion to MCI at year 3 (p=0.047 and p=0.022, respectively).

 

Our findings suggest that total hippocampal and hippocampal subfield volumes may reflect pathology contributing to cognitive impairment in PD.  Low total hippocampal, hippocampal tail, and CA1 volume at baseline significantly predict future cognitive impairment in PD.

Authors/Disclosures
Niels Bergsland (Buffalo Neuroimaging Analysis Center / State University of New York At Buffalo)
PRESENTER
Prof. Bergsland has nothing to disclose.
Robert Zivadinov, MD, PhD, FÂé¶¹´«Ã½Ó³»­ (Buffalo Neuroimaging Analysis Center) The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Omnicuris. The institution of Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Myrobalan. Dr. Zivadinov has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Zivadinov has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Zivadinov has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen.
No disclosure on file
Daniel Weintraub Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Clintrex. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scion. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunovion. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Modality.ai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CuraSen. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorder Society. The institution of Daniel Weintraub has received research support from NIH. The institution of Daniel Weintraub has received research support from Fox Foundation. The institution of Daniel Weintraub has received research support from IPMDS. Daniel Weintraub has received intellectual property interests from a discovery or technology relating to health care.
Thomas J. Guttuso, MD Dr. Guttuso has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Acorda. Dr. Guttuso has received stock or an ownership interest from e3 Pharmaceuticals.